181 related articles for article (PubMed ID: 37863681)
1. Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies.
Bilgihan MT; Eryigit AN; Ciftciler R
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):23-31. PubMed ID: 37863681
[TBL] [Abstract][Full Text] [Related]
2. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
5. Clinical Development of PD-1 Blockade in Hematologic Malignancies.
Pianko MJ; Goldberg AD; Lesokhin AM
Cancer J; 2018; 24(1):31-35. PubMed ID: 29360725
[TBL] [Abstract][Full Text] [Related]
6. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
8. [Immune-checkpoint inhibitors in hematologic malignancies].
Maruyama D
Rinsho Ketsueki; 2016; 57(11):2381-2387. PubMed ID: 27941289
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
10. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Ogasawara K; Newhall K; Maxwell SE; Dell'Aringa J; Komashko V; Kilavuz N; Delarue R; Czuczman M; Sternas L; Rose S; Beach CL; Novick S; Zhou S; Palmisano M; Li Y
Clin Pharmacokinet; 2020 Feb; 59(2):217-227. PubMed ID: 31332669
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
Hatic H; Sampat D; Goyal G
Ann Transl Med; 2021 Jun; 9(12):1037. PubMed ID: 34277837
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape.
Ebrahimi S; Habibzadeh A; Khojasteh-Kaffash S; Valizadeh P; Samieefar N; Rezaei N
Crit Rev Oncol Hematol; 2024 Jan; 193():104225. PubMed ID: 38049077
[TBL] [Abstract][Full Text] [Related]
15. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
16. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
18. B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.
Rogers BB
Clin J Oncol Nurs; 2020 Apr; 24(2):199-204. PubMed ID: 32196006
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade in hematologic malignancies.
Armand P
Blood; 2015 May; 125(22):3393-400. PubMed ID: 25833961
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials.
Guan J; Zhang J; Zhang X; Yuan Z; Cheng J; Chen B
Medicine (Baltimore); 2022 Dec; 101(50):e32333. PubMed ID: 36550903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]